Home
/
Cytosorbents Corp
/
Financials
/
Quarterly
Cytosorbents Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cytosorbents Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2019
Jun 30, 2019
$6.23M
Aug 6, 2019
Q1
2019
Mar 31, 2019
$5.19M
May 7, 2019
Q3
2018
Sep 30, 2018
$5.74M
Nov 6, 2018
Q2
2019
Jun 30, 2018
$5.76M
Aug 6, 2019
Q1
2019
Mar 31, 2018
$4.92M
May 7, 2019
Q3
2018
Sep 30, 2017
$3.82M
Nov 6, 2018
Q2
2018
Jun 30, 2017
$3.57M
Aug 2, 2018
Q2
2012
Jun 30, 2012
$33.0K
Aug 13, 2012
Q1
2012
Mar 31, 2012
$16.9K
May 15, 2012
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$4.92M
May 8, 2018
Q3
2017
Sep 30, 2017
$3.82M
Nov 9, 2017
Q2
2017
Jun 30, 2017
$3.57M
Aug 7, 2017
Q1
2018
Mar 31, 2017
$3.11M
May 8, 2018
Q3
2017
Sep 30, 2016
$2.41M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$2.22M
Aug 7, 2017
Q1
2017
Mar 31, 2016
$1.81M
May 8, 2017
Q3
2016
Sep 30, 2015
$1.34M
Nov 7, 2016
Q2
2016
Jun 30, 2015
$963.9K
Aug 9, 2016
Q1
2016
Mar 31, 2015
$723.1K
May 9, 2016
Q3
2015
Sep 30, 2014
$1.16M
Nov 13, 2015
Q2
2015
Jun 30, 2014
$1.02M
Aug 13, 2015
Q1
2015
Mar 31, 2014
$1.06M
May 11, 2015
Q3
2014
Sep 30, 2013
$880.7K
Nov 12, 2014
Q2
2014
Jun 30, 2013
$291.5K
Aug 12, 2014
Q1
2014
Mar 31, 2013
$371.3K
May 14, 2014
Q3
2013
Sep 30, 2012
$605.3K
Nov 6, 2013
Q2
2013
Jun 30, 2012
$83.0K
Aug 14, 2013
Q1
2013
Mar 31, 2012
$50.2K
May 15, 2013
Q3
2012
Sep 30, 2011
$0
Nov 21, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.17M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
$1.95M
Aug 7, 2025
Q1
2025
Mar 31, 2025
($1.48M)
May 14, 2025
Q3
2025
Sep 30, 2024
($2.77M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($4.29M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($6.09M)
May 14, 2025
Q3
2024
Sep 30, 2023
($9.19M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($6.15M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($7.33M)
May 9, 2024
Q3
2023
Sep 30, 2022
($12.20M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($10.88M)
Aug 1, 2023
Q1
2023
Mar 31, 2022
($8.97M)
May 2, 2023
Q3
2022
Sep 30, 2021
($6.41M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($4.68M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
($4.17M)
May 3, 2022
Q3
2021
Sep 30, 2020
($839.7K)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($2.87M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
($3.45M)
May 4, 2021
Q3
2020
Sep 30, 2019
($6.89M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($3.55M)
Aug 4, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.86M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($3.62M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($3.89M)
May 14, 2025
Q3
2025
Sep 30, 2024
($4.83M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($3.57M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($4.66M)
May 14, 2025
Q3
2024
Sep 30, 2023
($7.35M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($6.56M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($7.89M)
May 9, 2024
Q3
2023
Sep 30, 2022
($9.02M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($8.36M)
Aug 1, 2023
Q1
2023
Mar 31, 2022
($7.79M)
May 2, 2023
Q3
2022
Sep 30, 2021
($5.41M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($4.92M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
($2.85M)
May 3, 2022
Q3
2021
Sep 30, 2020
($1.96M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($3.30M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
($2.48M)
May 4, 2021
Q3
2020
Sep 30, 2019
($5.63M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($3.63M)
Aug 4, 2020